BACKGROUND AND OBJECTIVES: The contribution of urolithiasis, if any, to the development of ESRD is unclear. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: All stone formers in Olmsted County, Minnesota, first diagnosed between 1984 and 2008 were identified by diagnostic codes with up to four controls matched on age and sex. Charts were reviewed to validate symptomatic stone formers in a random subset. Incident ESRD events were identified by the US Renal Data System. RESULTS: Altogether, 51 stone formers and 75 controls developed ESRD among 6926 stone formers and 24,620 matched controls followed for a mean of 9 years. Stone formers had an increased risk of ESRD after adjusting for diabetes, hypertension, dyslipidemia, gout, and CKD (hazard ratio: 2.09; 95% confidence interval: 1.45-3.01). This increased risk of ESRD remained in the subset of 2457 validated symptomatic stone formers (hazard ratio: 1.95; 95% confidence interval: 1.09-3.49). The attributable risk of ESRD from symptomatic urolithiasis was 5.1% based on a prevalence of 5.4% for stone formers. For stone formers versus controls who developed ESRD, there was an increased likelihood of past hydronephrosis (44% versus 4%), recurrent urinary tract infections (26% versus 4%), acquired single kidney (15% versus 3%), neurogenic bladder (12% versus 1%), and ileal conduit (9% versus 0%), but not diabetes (32% versus 49%) or hypertension (44% versus 52%). CONCLUSIONS: Symptomatic stone formers are at increased risk for ESRD independent of several cardiovascular risk factors. Other urological disease is relatively common among stone formers who develop ESRD.
BACKGROUND AND OBJECTIVES: The contribution of urolithiasis, if any, to the development of ESRD is unclear. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: All stone formers in Olmsted County, Minnesota, first diagnosed between 1984 and 2008 were identified by diagnostic codes with up to four controls matched on age and sex. Charts were reviewed to validate symptomatic stone formers in a random subset. Incident ESRD events were identified by the US Renal Data System. RESULTS: Altogether, 51 stone formers and 75 controls developed ESRD among 6926 stone formers and 24,620 matched controls followed for a mean of 9 years. Stone formers had an increased risk of ESRD after adjusting for diabetes, hypertension, dyslipidemia, gout, and CKD (hazard ratio: 2.09; 95% confidence interval: 1.45-3.01). This increased risk of ESRD remained in the subset of 2457 validated symptomatic stone formers (hazard ratio: 1.95; 95% confidence interval: 1.09-3.49). The attributable risk of ESRD from symptomatic urolithiasis was 5.1% based on a prevalence of 5.4% for stone formers. For stone formers versus controls who developed ESRD, there was an increased likelihood of past hydronephrosis (44% versus 4%), recurrent urinary tract infections (26% versus 4%), acquired single kidney (15% versus 3%), neurogenic bladder (12% versus 1%), and ileal conduit (9% versus 0%), but not diabetes (32% versus 49%) or hypertension (44% versus 52%). CONCLUSIONS: Symptomatic stone formers are at increased risk for ESRD independent of several cardiovascular risk factors. Other urological disease is relatively common among stone formers who develop ESRD.
Authors: Stephen Madersbacher; Jochen Schmidt; Johannes M Eberle; Harriet C Thoeny; Fiona Burkhard; Werner Hochreiter; Urs E Studer Journal: J Urol Date: 2003-03 Impact factor: 7.450
Authors: Wonngarm Kittanamongkolchai; Kristin C Mara; Ramila A Mehta; Lisa E Vaughan; Aleksandar Denic; John J Knoedler; Felicity T Enders; John C Lieske; Andrew D Rule Journal: Clin J Am Soc Nephrol Date: 2017-02-01 Impact factor: 8.237
Authors: Kara L Watts; Abhishek Srivastava; Wilson Lin; Daniel Schoenfeld; Matthew Abramowitz; Joshua M Stern Journal: Urolithiasis Date: 2019-02-12 Impact factor: 3.436
Authors: Pietro Manuel Ferraro; Miguel Ángel Arrabal-Polo; Giovambattista Capasso; Emanuele Croppi; Adamasco Cupisti; Thomas Ernandez; Daniel G Fuster; Juan Antonio Galan; Felix Grases; Ewout J Hoorn; Felix Knauf; Emmanuel Letavernier; Nilufar Mohebbi; Shabbir Moochhala; Kremena Petkova; Agnieszka Pozdzik; John Sayer; Christian Seitz; Pasquale Strazzullo; Alberto Trinchieri; Giuseppe Vezzoli; Corrado Vitale; Liffert Vogt; Robert J Unwin; Olivier Bonny; Giovanni Gambaro Journal: Urolithiasis Date: 2019-03-08 Impact factor: 3.436
Authors: Tsering Dhondup; Wonngarm Kittanamongkolchai; Lisa E Vaughan; Ramila A Mehta; Jasdeep K Chhina; Felicity T Enders; LaTonya J Hickson; John C Lieske; Andrew D Rule Journal: Am J Kidney Dis Date: 2018-08-23 Impact factor: 8.860
Authors: Sushrut S Waikar; Anand Srivastava; Ragnar Palsson; Tariq Shafi; Chi-Yuan Hsu; Kumar Sharma; James P Lash; Jing Chen; Jiang He; John Lieske; Dawei Xie; Xiaoming Zhang; Harold I Feldman; Gary C Curhan Journal: JAMA Intern Med Date: 2019-04-01 Impact factor: 21.873
Authors: Pietro Manuel Ferraro; Ferraro Pietro Manuel; Alessandro D'Addessi; D'Addessi Alessandro; Giovanni Gambaro; Gambaro Giovanni Journal: Urolithiasis Date: 2014-08-06 Impact factor: 3.436
Authors: Saeed R Khan; Margaret S Pearle; William G Robertson; Giovanni Gambaro; Benjamin K Canales; Steeve Doizi; Olivier Traxer; Hans-Göran Tiselius Journal: Nat Rev Dis Primers Date: 2016-02-25 Impact factor: 52.329